Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Survival Prolongation by Rationale Innovative Genomics
NCT03386929 · Worldwide Innovative Network Association · PHASE1/PHASE2 · terminated · last registry update 2023-12-18 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to the absence of funding necessary for the performance of the Phase 2.” | Open Targets' class: business administrative | Registry record, Worldwide Innovative Network Association |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-13Phase 3 first posted: National Cancer Institute (NCI), Ceralasertib + Durvalumab (NCT06732401)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Atezolizumab (NCT06712355)
- 2024-10-17Phase 3 first posted: Bristol-Myers Squibb, BMS-986489 (Atigotatug+Nivolumab) + Atezolizumab (NCT06646276)
- 2024-10-09Phase 3 first posted: Alliance for Clinical Trials in Oncology, Cisplatin + Carboplatin (NCT06632327)
- 2024-07-12Phase 3 first posted: National Cancer Institute (NCI), Durvalumab (NCT06498635)
- 2024-02-28Phase 3 first posted: ETOP IBCSG Partners Foundation, Adjuvant durvalumab (NCT06284317)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
- 2023-01-18Phase 3 first posted: AstraZeneca, Datopotamab deruxtecan + Durvalumab (NCT05687266)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision